|
Aug 1
|
Eli Lilly’s Mounjaro shows cardiovascular gains, but analysts underwhelmed
|
|
Aug 1
|
Novo Nordisk shares hit lowest level in over 3-years
|
|
Aug 1
|
Novo Nordisk, other European pharma stocks fall after Trump raises stakes over US drug price cuts
|
|
Aug 1
|
Merck & Co. assembles an Alzheimer’s comeback with a next-gen precision focus
|
|
Aug 1
|
Trump Demands Pharma Companies to Lower US Prices
|
|
Aug 1
|
Trump doubles down on Most Favored Nation plan to target drug prices
|
|
Jul 31
|
Stock Market Today: Indexes Swing Lower While Amazon Rises Ahead Of Earnings; Apple Fades; IPO Figma Soars 277%
|
|
Jul 31
|
What Trump's Big Pharma CEO letters mean for drug pricing power
|
|
Jul 31
|
Eli Lilly and Company (LLY): We Sold Some Lilly, Says Jim Cramer
|
|
Jul 31
|
Trump sends letters to pharma CEOs demanding they reduce drug prices in 60 days
|
|
Jul 31
|
Trump Sends Letters to 17 Pharmaceutical Companies Asking Them to Lower Costs
|
|
Jul 31
|
Trump pressures 17 pharma CEOs to cut US drug prices
|
|
Jul 31
|
Trump demands largest pharma companies slash US drug prices
|
|
Jul 31
|
Eli Lilly (LLY) Reveals Promising Diabetes and Alzheimer's Trials Results
|
|
Jul 31
|
Targeting energy expenditure: the next wave of obesity drugs
|
|
Jul 31
|
Eli Lilly Weight-Loss Drug Makes Cardio Advance. More Bad News for Novo Nordisk.
|
|
Jul 31
|
What Makes Eli Lilly and Company (LLY) a Lucrative Investment?
|
|
Jul 31
|
Lilly stock falls as Mounjaro fails to show superiority over Trulicity
|
|
Jul 31
|
Biogen lifts full-year outlook amid Alzheimer’s drug strength, sending shares up
|
|
Jul 31
|
Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease
|